ProBioGen AG announced today that Serono S.A., Switzerland has signed an Agreement to evaluate ProBioGen's novel human neuronal cell line for the production of recombinant proteins.
Under the terms of the Agreement, Serono will explore the feasibility of using the proprietary neuronal cell line of ProBioGen as a host for the production of recombinant proteins. Financial details are not disclosed.
“Our human neuronal cell lines not only have the advantage of producing proteins with human glycosylation patterns, but they also have been developed with a fully documented history, a very important prerequisite for smooth approval of products derived from a cell line," said Michael Schlenk, CEO of ProBioGen AG. "In addition, they have a very high productivity, so we think we have created cell lines that can produce human biopharmaceuticals very cost effectively and with a very high safety profile. We are very glad that we won Serono as the first partner to explore the huge potential of these cell lines as Serono has a lot of experience in developing recombinant proteins.”
Press release Box-ID: 58225
ProBioGen AG
Goethestr. 54
13086
Berlin,
Germany
http://www.probiogen.de
Contact
Dr.
Hing Kin
Chan
+49 30 924006147
ProBioGen AG
ProBioGen is a cell specialist. By combining deep molecular understanding of cells with state-of-the-art industry process engineering and production know-how, ProBioGen's technologies enable biopharmaceutical companies to develop products with superior efficiency, safety and a more favourable cost profile. Since its inception in 1994, the company has processed more than 300 cell lines and established a GMP unit based on disposable reactor technology, which supports all currently available manufacturing processes. The company is headquartered in Berlin.
For more information, please visit www.probiogen.de
